Trial · NCT01436994
Antithyroid Drug Treatment of Thyrotoxicosis in Young People
NCT01436994, Phase 3, Completed, Newcastle-upon-Tyne Hospitals NHS Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antithyroid Drug Treatment of Thyrotoxicosis in Young People. Trials, record NCT01436994. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01436994
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antithyroid Drug Treatment of Thyrotoxicosis in Young People
- NCT number
- NCT01436994
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 81 participants, actual
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Conditions
- Paediatric Thyrotoxicosis
- Interventions
- Block and Replace, Dose Titration, carbimazole, propylthiouracil, thyroxine
- First posted
- 2011-09-20
- Last updated
- 2016-09-21
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Biochemical control as reflected by the stability of blood thyroid stimulating hormone (TSH) concentrations | 2.5 years | For each patient, TSH will be determined at each visit: the primary outcome variable is obtained by measuring the proportion of TSH concentrations that are outwith the laboratory normal range (in calculating this value, determinations made within six months of diagnosis are ignored). |
| Secondary | Remission rates as defined by patients who are biochemically euthyroid at the end of the 4 year study period. | 4 years | To establish whether the remission rates post therapy in young people with thyrotoxicosis are affected by treatment with a 'block and replace' or 'dose titration' regimen. This will be determined by determining the proportion of individuals who are in remission ie who are biochemically euthyroid off ATD-thyroid drug therapy at the end of the of the study period (4 years). The proportion of subjects in remission following block and replace therapy will therefore be compared with the proportion in remission following dose titration. |
| Secondary | The frequency of adverse events on the 2 treatment regimens. | 3 years | This will be reflected by the number of participants with adverse events and by the proportion of patients changing to a different treatment during the study period. |
| Secondary | Additional measures of biochemical control. | 3 years | A comparison of the mean and variability of TSH and thyroid hormone concentrations in the 2 treatment groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01436994
GET https://conductscience.org/api/trials/v1/NCT01436994/registered